Efficacy of tosedostat a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial

被引：1

作者：

Mathisen, Michael S. ^{[1
]}

Ravandi, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2012年 / 8卷 / 04期

关键词：

acute myeloid leukemia; aminopeptidase inhibitor; elderly relapsed; tosedostat; RISK MYELODYSPLASTIC SYNDROME; ACUTE MYELOGENOUS LEUKEMIA; INTENSIVE CHEMOTHERAPY; OLDER PATIENTS; GEMTUZUMAB OZOGAMICIN; CYTARABINE; INHIBITOR; COMBINATION; CLOFARABINE; IDARUBICIN;

D O I：

10.2217/FON.12.17

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukemia is most often diagnosed in patients older than 60 years of age. Overall, these patients have a poor prognosis, partly because they are typically unable to tolerate intensive chemotherapy regimens traditionally offered to younger individuals. Furthermore, responses attained in these older patients are not durable, with most experiencing relapse within 1-2 years. Therefore, new strategies are needed to improve the outcome of older patients with acute myeloid leukemia. Tosedostat is an orally available aminopeptidase inhibitor shown to have activity in leukemia. This commentary discusses the background and results of an ongoing Phase II evaluation of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia. The data available to date is analyzed and future perspectives regarding the development of this agent is discussed.

引用

页码：351 / 357

页数：7

共 42 条

[1]

Appelbaum F, 2006, BLOOD, V107, P53

[2] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia [J].

Attar, Eyal C. ;

De Angelo, Daniel J. ;

Supko, Jeffrey G. ;

D'Amato, Ferdinando ;

Zahrieh, David ;

Sirulnik, Andres ;

Wadleigh, Martha ;

Ballen, Karen K. ;

McAfee, Steve ;

Miller, Kenneth B. ;

Levine, James ;

Galinsky, Ilene ;

Trehu, Elizabeth G. ;

Schenkein, David ;

Neuberg, Donna ;

Stone, Richard M. ;

Amrein, Philip C. .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1446-1454

[3] Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine [J].

Blum, William ;

Garzon, Ramiro ;

Klisovic, Rebecca B. ;

Schwind, Sebastian ;

Walker, Alison ;

Geyer, Susan ;

Liu, Shujun ;

Havelange, Violaine ;

Becker, Heiko ;

Schaaf, Larry ;

Mickle, Jon ;

Devine, Hollie ;

Kefauver, Cheryl ;

Devine, Steven M. ;

Chan, Kenneth K. ;

Heerema, Nyla A. ;

Bloomfield, Clara D. ;

Grever, Michael R. ;

Byrd, John C. ;

Villalona-Calero, Miguel ;

Croce, Carlo M. ;

Marcucci, Guido .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (16) :7473-7478

[4] Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group [J].

Buechner, Thomas ;

Berdel, Wolfgang E. ;

Haferlach, Claudia ;

Haferlach, Torsten ;

Schnittger, Susanne ;

Mueller-Tidow, Carsten ;

Braess, Jan ;

Spiekermann, Karsten ;

Kienast, Joachim ;

Staib, Peter ;

Grueneisen, Andreas ;

Kern, Wolfgang ;

Reichle, Albrecht ;

Maschmeyer, Georg ;

Aul, Carlo ;

Lengfelder, Eva ;

Sauerland, Maria-Cristina ;

Heinecke, Achim ;

Woermann, Bernhard ;

Hiddemann, Wolfgang .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :61-69

[5]

Burnett AK, 2011, BLOOD, V118

[6] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[7] European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Kell, Jonathan ;

Dennis, Michael ;

Milligan, Donald ;

Paolini, Stefania ;

Yin, John ;

Culligan, Dominic ;

Johnston, Peter ;

Murphy, John ;

McMullin, Mary-Frances ;

Hunter, Ann ;

Das-Gupta, Emma ;

Clark, Richard ;

Carr, Robert ;

Hills, Robert K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2389-2395

[8] Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia [J].

Cashen, Amanda F. ;

Schiller, Gary J. ;

O'Donnell, Margaret R. ;

DiPersio, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :556-561

[9] Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA) [J].

Castaigne, Sylvie ;

Pautas, Cecile ;

Terre, Christine ;

Raffoux, Emmanuel ;

Bordessoule, Dominique ;

Bastie, Jean-Noel ;

Legrand, Ollivier ;

Thomas, Xavier ;

Turlure, Pascal ;

Reman, Oumedaly ;

De Revel, Thierry ;

Gastaud, Lauris ;

Gardin, Claude ;

Sutton, Laurent ;

Marolleau, Jean Pierre ;

De Botton, Stephane ;

Hermine, Olivier ;

Plantier, Isabelle ;

Janvier, Maud ;

Dupriez, Brigitte ;

Simon, Marc ;

De Gunzburg, Noemie ;

Foucault-Haiat, Stephanie ;

Contentin, Nathalie ;

Berthon, Celine ;

Fenaux, Pierre ;

Henry, Estelle ;

Rousselot, Philippe ;

Preudhomme, Claude ;

Chevret, Sylvie ;

Dombret, Herve .

BLOOD, 2011, 118 (21) :5-5

[10] Gemtuzumab ozogamicin: is there room for salvage? [J].

Clarke, W. Thomas ;

Marks, PeterW. .

BLOOD, 2010, 116 (14) :2618-2619

← 1 2 3 4 5 →